NOS2 and lung carcinoma: Accordingly, direct targeting iNOS via inhibitors such as 1400w reduced MDSC expansion in both primary tumour and metastatic sites in a mouse model of lung cancer, and strikingly potentiated the anti-tumour treatment efficacy of anti-PD-L1 immune checkpoint inhibition [70].